Treatment Discontinuation
Tirzepatide discontinuation due to adverse events (primarily GI) is a clinically relevant concern given the drug’s long-term use requirement for sustained glycaemic and weight benefit. The discontinuation rate is dose-dependent: approximately 3% (5mg), 6% (10mg), and 10% (15mg) based on systematic review data from 10 trials, 6836 participants (Mishra et al., 2023). This is higher than the discontinuation rate for semaglutide 1mg (4%), glargine (1–5%), and placebo (3%), with the difference most pronounced at the highest dose.
The systematic review by Karagiannis et al. (Diabetologia 2022, PMID 35579691) confirmed that tirzepatide 15mg had the highest discontinuation rate regardless of comparator. Most discontinuations are attributable to nausea, vomiting, and diarrhoea — occurring primarily during dose escalation. The 4-week dose titration schedule (starting at 2.5mg, escalating every 4 weeks) was designed to reduce but not eliminate this risk.
In real-world practice, discontinuation rates may differ from trial rates due to differences in patient selection, motivational factors, and prescriber support. Trial populations are typically more motivated and closely monitored than real-world patients.
Ontology Treatment Discontinuation [warns_about] Tirzepatide Treatment Discontinuation [relates] Nausea and Vomiting Risk
Numbers
- Discontinuation due to AE: 3% (5mg), 6% (10mg), 10% (15mg) — dose-dependent
- Overall GI AEs (any): 39% (5mg), 46% (10mg), 49% (15mg)
- Comparators: placebo 3%, semaglutide 1mg 4%, basal insulin 1–5%
- Source: 10 trials, 6836 participants (Mishra et al., J Endocr Soc 2023)
Practical Interpretation
- Most at risk: Higher-dose patients (10mg, 15mg) and GI-sensitive patients
- Evidence type: Meta-analysis of RCTs; real-world rates may vary
- Mitigation: Slow dose escalation (every 4 weeks); dose reduction if GI events severe
Connections
- Tirzepatide — warns_about
- Nausea and Vomiting Risk — relates